The clinical significance of FLT3 ITD mutation on the prognosis of adult acute promyelocytic leukemia

被引:12
|
作者
Fan, Yingchao [1 ]
Cao, Yanan [1 ]
Bai, Xiaosong [1 ]
Zhuang, Wenfang [1 ]
机构
[1] Shidong Hosp Yangpu Dist, Dept Lab Diag, Shanghai, Peoples R China
关键词
FLT3; acute promyelocytic leukemia; 5-year OS; 5-year DFS; CR rate; meta-analysis; survival; odds ratio; ACUTE MYELOID-LEUKEMIA; INTERNAL TANDEM DUPLICATION; TRANS-RETINOIC ACID; RAS GENE-MUTATIONS; ARSENIC TRIOXIDE; RISK GROUP; THERAPY; IMPACT; INDUCTION; CONSOLIDATION;
D O I
10.1080/10245332.2017.1415717
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and aims: To explore the relationship between FLT3 (encoding Fms related tyrosine kinase 3) internal tandem duplication (ITD) mutations with the prognosis of acute promyelocytic leukemia. The PubMed database, the Cochrane Library, conference proceedings, the EMBASE databases, and references of published trials and review articles were searched. Two reviewers independently assessed the quality of the trials and extracted the data. Odd ratios (ORs) for complete remission (CR) rate after induction therapy, 5-year overall survival (OS), and 5-year disease free survival (DFS) were pooled using the STATA package. Main results: Seventeen trials involving 2252 patients were ultimately analyzed. The pooled OR showed that the FLT3 ITD mutation group had a poor prognosis in terms of CR rate (OR = 0.53, 95% confidence interval (CI), 0.30-0.95, P= 0.03), 5-year OS (OR = 0.47, 95% CI, 0.29-0.75, P= 0.002), and as 5-year DFS (OR = 0.48, 95% CI, 0.29-0.78; p= 0.003). Conclusions: The results suggested that FLT3 ITD mutations could become an indicator of poor prognosis of APL, and these patients should receive more intensive therapy according to current guidelines.
引用
收藏
页码:379 / 384
页数:6
相关论文
共 50 条
  • [41] The Clinical Utility of FLT3 Mutation Testing in Acute Leukemia: A Canadian Consensus
    Bergeron, Julie
    Capo-Chichi, Jose-Mario
    Tsui, Hubert
    Mahe, Etienne
    Berardi, Philip
    Minden, Mark D.
    Brandwein, Joseph M.
    Schuh, Andre C.
    CURRENT ONCOLOGY, 2023, 30 (12) : 10410 - 10436
  • [42] FLT3 and acute myelogenous leukemia: Biology, clinical significance and therapeutic applications
    Advani, AS
    CURRENT PHARMACEUTICAL DESIGN, 2005, 11 (26) : 3449 - 3457
  • [43] The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status
    Green, Claire L.
    Evans, Catherine M.
    Hills, Robert K.
    Burnett, Alan K.
    Linch, David C.
    Gale, Rosemary E.
    BLOOD, 2010, 116 (15) : 2779 - 2782
  • [44] Impact of FLT3 ITD/NPM1 mutation status in adult patients with acute myelocytic leukemia autografted in first remission
    Gorin, Norbert-Claude
    Labopin, Myriam
    Meloni, Giovanna
    Pigneux, Arnaud
    Esteve, Jordi
    Mohty, Mohamad
    HAEMATOLOGICA, 2013, 98 (02) : E12 - E14
  • [45] PROGNOSTIC IMPLICATION OF FLT3 MUTATIONS IN PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA
    Pagoni, M.
    Garofalaki, M.
    Tziotziou, I.
    Nikolou, E.
    Panitsas, F.
    Bika, I.
    Tzannou, I.
    Vourtsi, A.
    Delimpassi, S.
    Gigantes, S.
    Harhalakis, N.
    ANNALS OF HEMATOLOGY, 2011, 90 : S7 - S7
  • [46] PRE-CLINICAL EVALUATION OF NOVEL FLT3 INHIBITORS EFFECTIVE IN FLT3-ITD ACUTE MYELOID LEUKEMIA
    Minson, Katherine
    Sherick, Alisa Lee
    DeRyckere, Deborah
    Wang, Xiaodong
    Frye, Stephen
    Earp, H. Shelton, III
    Graham, Doug
    PEDIATRIC BLOOD & CANCER, 2014, 61 : S52 - S52
  • [47] The combination of FLT3 and DNA methyltransferase inhibition is synergistically cytotoxic to FLT3/ITD acute myeloid leukemia cells
    E Chang
    S Ganguly
    T Rajkhowa
    C D Gocke
    M Levis
    H Konig
    Leukemia, 2016, 30 : 1025 - 1032
  • [48] The combination of FLT3 and DNA methyltransferase inhibition is synergistically cytotoxic to FLT3/ITD acute myeloid leukemia cells
    Chang, E.
    Ganguly, S.
    Rajkhowa, T.
    Gocke, C. D.
    Levis, M.
    Konig, H.
    LEUKEMIA, 2016, 30 (05) : 1025 - 1032
  • [49] Synergistic Effect of SGN-CD33A and FLT3 Inhibitors in FLT3/ITD Acute Myeloid Leukemia
    Tarlock, Katherine
    Thurman, Robert
    Rohm, Rory
    Biechele, Travis
    Arthur, Bill
    Meshinchi, Soheil
    BLOOD, 2018, 132
  • [50] FLT3 Mutation in Acute Myeloid Leukemia: Primary or Secondary Mutation?
    Ma, Wanlong
    De Dios, Ivan
    Funari, Vincent
    Sudarsanam, Sucha
    Jiang, Shi-Ping
    Agersborg, Sally
    Hummel, Jennifer
    Blocker, Forrest
    Albitar, Maher
    BLOOD, 2017, 130